eOphtha

Menu

 


 

Acetazolamide | Acetylcholine | Acyclovir | Adalimumab | Amikacin | Amphotericin B | Ampicillin | Apraclonidine| Atropine | Azathioprine | Azelastine | Betaxolol | Bevacizumab| Biologicals | Brimonidine | Brinzolamide  | Bupivacaine | Capsofungin  | Cefazolin | Cidofovir | Ciprofloxacin | Clotrimazole | Corticosteroids | Cyclopentolate | Cyclosporine A | Cyclophosphamide | Daclizumab | Dorzolamide | EDTA | Epinephrine | Etanercept| Erythromycin | Famciclovir | Foscarnet | Fluconazole | Fluorescein Sodium | Fluorometholone | 5-Fluorouracil | Flurbiprofen   | Ganciclovir | Gatifloxacin | Gentamicin | Glycerin | Homatropine | Hydroxypropyl | Idoxurudine | Indocyanine Green | Infliximab | Interferon alpha | Itraconazole | Ketoconazole | Ketorolac | Latanoprost | Leflunomide | Lidocaine | Loteprednol | Mannitol  | Methotrexate | Methylene Blue | Mitomycin | Moxifloxacin | Mycophenolate Mofetil | Naphazoline | Natamycin | Nedocromil Sodium | Neomycin Sulfate | Ofloxacin | Olopatadine | Pegaptanib | Pilocarpine | Timolol | Valacyclovir | Valganciclovir | Vidarabine | Voriconazole

Etanercept

Eternercept is an engineered recombinant dimeric protein. The drug was first approved for the treatment of rheumatoid arthritis. It has been tried for the treatment of chronic anterior uveitis in children, but the results are less encouraging than that of infliximab . This may be due to the infliximab’s dosage flexiblity and its ability to bind both soluble and membrane-bound TNF .

•  First synthesised and pateted by by Bruce A. Beutler, an academic researcher then at the University of Texas Southwestern Medical Center at Dallas, and his colleagues
•  Etanercept is not actually a monoclonal antibody though it is termed as antibody like drug.
•  It has a short half life of 4 days and bioavailibility of 58–76% when administered by subcutaneous route
•  The drug has received FDA approval in June, 2003 for treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis.

 

Mechanism of Action

It acts by competitively inhibiting the binding with TNF-α & TNF-β with their receptors.Read more

Dosage & Pharmacokinetics

Infliximab forms stable bonds with both soluble and transmembrane forms of TNF-α, where as etanercept forms a weak bond with transmembrane forms. Eternecept is injected subcutaeously .The dosage is 25 mg twice a week.

Side effects

The side effects of Etanercept are similar to that of Infliximab.

Also read

Biologicals , TNF-alpha Blocker

Statutory Warning

Materials / Informations provided here are for educational purpose only ; and not to be used for medical advice, diagnosis or treatment